Abstract
Both altered GH-IGF-I axis and low serum levels of 25-hydroxyvitamin D (25(OH)D) are linked to measures of metabolic syndrome. Our hypothesis was that there is a relation between GH, IGF-I, and 25(OH)D; and that vitamin D supplementation may have an effect on the levels of GH, IGF-I, and IGF-I/IGFBP-3 ratio. 318 overweight and obese subjects completed a one-year randomized intervention with either 40,000 or 20,000 IU cholecalciferol per week or placebo. GH, IGF-I, IGFBP-3 and measures of insulin resistance were evaluated at baseline and at the end of study. There was a significant relation between entities of GH-IGF-I axis and insulin resistance. Subjects with severe obesity had significantly lower serum 25(OH)D and had a significant linear decline in IGF-I/IGFBP-3 ratio with increasing serum 25(OH)D quartiles. Vitamin D status was an independent predictor of GH-IGF-I axis and supplementation with vitamin D decreased IGF-I/IGFBP-3 ratio in subjects without severe obesity. No corresponding effect of vitamin D supplementation on BMI or insulin resistance was observed. Adverse effects of GH-IGF-I axis on glucose metabolism and the development of metabolic syndrome may be in part associated with the changes in vitamin D status.
Similar content being viewed by others
References
J.M. Gómez, F.J. Maravall, N. Gómez, M.A. Navarro, R. Casamitjana, J. Soler, Interactions between serum leptin, the insulin-like growth factor-1 system, and age, sex, anthropometric and body composition variables in a healthy population randomly selected. Clin. Endocrinol. 58, 213–219 (2003)
M.S. Sandhu, A.H. Heald, J.M. Gibson, J.K. Cruickshank, D.B. Dunger, N.J. Wareham, Circulating concentrations of insulin-like growth factor-1 and development of glucose intolerance: a prospective observational study. Lancet 359, 1740–1745 (2002)
H.J. Schneider, H. Wallaschofski, H. Völzke, M.R. Markus, M. Doerr, S.B. Felix, M. Nauck, N. Friedrich, Incremental effects of endocrine and metabolic biomarkers and abdominal obesity on cardiovascular mortality prediction. PLoS ONE 7(3), e33084 (2012)
H. Völzke, M. Nauck, R. Rettig, M. Dörr, C. Higham, G. Brabant, H. Wallaschofski, Association between hepatic steatosis and serum IGF1 and IGFBP3 levels in a population-based sample. Eur. J. Endocrinol. 161, 705–713 (2007)
A.H. Paredes, D.M. Torres, S.A. Harrison, Nonalcoholic fatty liver disease. Clin. Liver Dis. 16, 397–419 (2012)
S. Rajaram, D.J. Baylink, S. Mohan, Insulin-like growth factor binding proteins in serum and other biological fluids: regulations and functions. Endocr. Rev. 18, 381–801 (1997)
S.Y. Nam, E.J. Lee, K.R. Kim, B.S. Cha, Y.D. Song, S.K. Lim, H.C. Lee, K.B. Huh, Effect of obesity on total and free insulin-like growth factor (IGF)-1, and their relationship to IGF-binding protein (BP)-1, IGFBP-2, IGFBP-3, insulin, and growth hormone. Int. J. Obes. Rel. Metab. Disord. 21, 355–359 (1997)
A. Juul, K. Main, W.F. Blum, J. Lindholm, M.B. Ranke, N.E. Skakkebaek, The ratio between serum levels of insulin-like growth factor (IGF)-1 and the IGF binding proteins (IGFBP-1, 2 and 3) decreases with age in healthy adults and is increased in acromegalic patients. Clin. Endocrinol. 41, 85–93 (1994)
M.A. Kirschner, N. Ertel, G. Schneider, Obesity, hormones, and cancer. Cancer Res. 41, 3711–3717 (1981)
P. Mårin, R. Rosmond, B.A. Bengtsson, C. Gustafsson, G. Holm, P. Björntorp, Growth hormone secretion after testosterone administration to men with visceral obesity. Obes. Res. 2, 263–270 (1994)
M. Wabitsch, GH/IGF axis and longitudinal growth in children with obesity. J. Pediatr. Gastroenterol. Nutr. 51S, 145–146 (2010)
J. Pineda, C. Dieguez, F.F. Casanueva, P. Martul, Decreased growth hormone response to dexamethasone stimulation test in obese children. Acta Paediatr. 83, 103–105 (1994)
R.S. Yalow, S.M. Glick, J. Roth, S.A. Berson, Plasma and insulin and growth hormone levels in obesity and diabetes. Ann. N. Y. Acad. Sci. 131, 373–375 (1965)
S. Yakar, J.L. Liu, B. Stannard, A. Butler, D. Accili, B. Sauer, D. LeRoith, Normal growth and development in the absence of hepatic insulin-like growth factor 1. Proc. Nat. Acad. Sci. 96, 7324–7329 (1999)
M. Wabitsch, E. Heinze, K.M. Debatin, W.F. Blum, IGF-1 and IGFBP-3-expression in cultured human preadipocytes and adipocytes. Horm. Metab. Res. 32, 555–559 (2000)
A. Guistina, G. Mazziotti, E. Canalis, Growth hormone, insulin-like growth factors, and the skeleton. Endocr. Rev. 29, 535–559 (2008)
K.E. Wong, J. Kong, W. Zhang, F.L. Szeto, H. Ye, D.K. Deb, M.J. Brady, Y.C. Li, Targeted expression of human vitamin D receptor in adipocytes decreases energy expenditure and induces obesity in mice. J. Biol. Chem. 30, 3804–3810 (2011)
J.A. Johnson, J.P. Grande, P.C. Roche, R. Kumar, Immunohistochemical detection and distribution of the 1,25-dihydroxyvitamin D3 receptor in rat reproductive tissues. Histochem. Cell Biol. 105, 7–15 (1996)
E. Kamycheva, R. Jorde, Y. Figenschau, E. Haug, Insulin sensitivity in subjects with secondary hyperparathyroidism and the effect of a low serum 25-hydroxyvitamin D level on insulin sensitivity. J. Endocrinol. Invest. 30, 126–132 (2007)
P. Lips, Vitamin D physiology. Prog. Biophys. Mol. Biol. 92, 4–8 (2006)
P.R. von Hurst, W. Stonehouse, J. Coad, Vitamin D supplementation reduces insulin resistance in South Asian women living in New Zealand who are insulin resistant and vitamin D deficient- a randomised, placebo-controlled trial. Br. J. Nutr. 103, 549–555 (2010)
N.C. Bozkurt, E. Cakal, M. Sahin, E.C. Ozkaya, H. Firat, T. Delibasi, The relation of serum 25-hydroxyvitamin D levels with severity of obstructive sleep apnea and glucose metabolism abnormalities. Endocrine 41, 518–525 (2012)
M. Sneve, Y. Figenschau, R. Jorde, Supplementation with cholecalciferol does not result in weight reduction in overweight and obese subjects. Eur. J. Endocrinol. 159, 675–684 (2008)
B.L. Fisher, P. Schauer, Medical and surgical options in the treatment of severe obesity. Am. J. Surg. 184, S9–S16 (2002)
H. Fukuoka, Y. Takahashi, K. Iida, T. Kudo, H. Nishizawa, M. Imanaka, R. Takeno, G. Iguchi, K. Takahashi, Y. Okimura, H. Kaji, K. Chinara, Low serum IGF-1/GH ratio is associated with abnormal glucose tolerance in acromegaly. Horm. Res. 69, 165–171 (2008)
Y. Kinishita, H. Fujii, A. Takeshita, M. Taguchi, M. Miyakawa, K. Oyama, S. Yamada, Y. Takeuchi, Impaired glucose metabolism in Japanese patients with acromegaly is restored after successful pituitary surgery if pancreatic β-cell function is preserved. Eur. J. Endocrinol. 164, 467–473 (2011)
A. Denley, J.M. Carrol, G.V. Cosgrove, J. Wallace, B. Forbes, C.T. Roberts Jr, Differential activation of insulin receptor substrates 1 and 2 by insulin-like growth factor-activated insulin receptors. Mol. Cell. Biol. 27, 3569–3577 (2007)
K. Cleveland-Donovan, L. Maile, W.G. Tsiara, T. Tchkonia, J. Kirkland, C.M. Boney, IGF-1 activation of the AKT pathway is impaired in visceral but not subcutaneous preadipocytes from obese subjects. Endocrinology 151, 3752–3763 (2010)
D.E. Berryman, E.O. List, K.T. Coschigano, K. Behar, J.K. Kim, J.J. Kopchik, Comparing adiposity profiles in three mouse models with altered GH signalling. Growth. Horm. IGF Res. 14, 309–318 (2004)
A. Guistina, J.D. Veldhuis, Pathophysiology of the neuroregulation of growth hormone secretion in experimental animals and the human. Endocr. Rev. 19, 717–797 (1998)
H.W. Davidson, C.J. Rhodes, J.C. Hutton, Intraorganellar calcium and PH control proinsulin cleavage in the pancreatic beta cell via two distinct site-specific endopeptidases. Nature 333, 93–96 (1988)
E. Hyppönen, B.J. Boucher, D.J. Berry, C. Power, 25-hydroxyvitamin D, IGF-1, and metabolic syndrome at 45 years of age. Diabetes 57, 298–305 (2008)
M. Matilainen, M. Malinen, K. Saavalainen, C. Carlberg, Regulation of multiple insulin-like growth factor binding protein genes by 1alpha,25hydroxyvitamin D3. Nucl. Acid Res. 33, 5521–5532 (2005)
J.M. Gómez, The role of insulin-like growth factor 1 components in the regulation of vitamin D. Curr. Pharm. Biotechnol. 7, 125–132 (2006)
H.O. El-Mesallamy, N.M. Hamdy, A.M. Sallam, Effect of obesity and glycemic control on serum lipocalins and insulin-like growth factor axis in type 2 diabetic patients. Acta Diabetolog. Epub ahead of print (2012)
Acknowledgments
The study was supported by a grant from The Northern Norway Regional Health Authority. The superb assistance by the staff at the Clinical Research Unit and by Inger Myrnes and Astrid Lindvall at the Department of Medical Biochemistry, University Hospital of Northern Norway, is gratefully acknowledged. We are grateful for the generous supply of calcium tablets from Nycomed Norway.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Kamycheva, E., Berg, V. & Jorde, R. Insulin-like growth factor I, growth hormone, and insulin sensitivity: the effects of a one-year cholecalciferol supplementation in middle-aged overweight and obese subjects. Endocrine 43, 412–418 (2013). https://doi.org/10.1007/s12020-012-9825-6
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s12020-012-9825-6